A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...
Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...
Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...
The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of ...
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...
Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, ...
If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...
Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...
A spokesperson for the FDA said the agency is “considering a wide range of options to support American innovation." ...
Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high ...
In May, a BioSpace survey found that 56% of employed biopharma professionals are considering jobs outside the industry. Among the unemployed, that number jumps to 81%. In another pulse check, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback